fusion-pharma.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-Agent: * Disallow: /page1026518.html Disallow: /menu Disallow: /page1026552.html Disallow: /footer Disallow: /tilda/form* Disallow: /tilda/rec* Disallow: /tilda/click* Disallow: /tilda/scroll* Disallow: /tilda/popup* Disallow: /tilda/cart* Disallow: /tilda/product* Disallow: /tilda/event* Disallow: /*_escaped_fragment_* Disallow: Sitemap: http://fusion-pharma.com/sitemap.xml Host: | ||
Meta Tags
| Title | Fusion |
| Description | This page contains useful information for patients who might want to participate in clinical trial of |
| Keywords | PF-114, PF114, clinical trial, CML, chronic myeloid leukemia |
Server Information
| WebSite | |
| Host IP | 172.67.218.158 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
fusion-pharma.com Valuation
|
US$419,773
Last updated: 2023-05-13 11:49:00
fusion-pharma.com has Semrush global rank of 25,214,372. fusion-pharma.com has an estimated worth of US$ 419,773, based on its estimated Ads revenue. fusion-pharma.com receives approximately 48,436 unique visitors each day. Its web server is located in United States, with IP address 172.67.218.158. According to SiteAdvisor, fusion-pharma.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$419,773 |
| Daily Ads Revenue | US$388 |
| Monthly Ads Revenue | US$11,625 |
| Yearly Ads Revenue | US$139,494 |
| Daily Unique Visitors | 3,230 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| fusion-pharma.com. | A | 299 | IP: 172.67.218.158 |
| fusion-pharma.com. | A | 299 | IP: 104.21.78.84 |
| fusion-pharma.com. | AAAA | 299 | IPV6: 2606:4700:3034::6815:4e54 |
| fusion-pharma.com. | AAAA | 299 | IPV6: 2606:4700:3036::ac43:da9e |
| fusion-pharma.com. | NS | 86400 | NS Record: matt.ns.cloudflare.com. |
| fusion-pharma.com. | NS | 86400 | NS Record: deb.ns.cloudflare.com. |
| fusion-pharma.com. | MX | 300 | MX Record: 5 mx02.nicmail.ru. |
| fusion-pharma.com. | MX | 300 | MX Record: 10 mx01.nicmail.ru. |
| fusion-pharma.com. | MX | 300 | MX Record: 20 mx03.nicmail.ru. |
| fusion-pharma.com. | TXT | 300 | TXT Record: v=spf1 redirect=nicmail.ru |
HtmlToTextCheckTime:2023-05-13 11:49:00
| FOR PATIENTS ABOUT US TECHNOLOGY NEWS CONTACT US ENG RUS FOR PATIENTS ABOUT US TECHNOLOGY NEWS CONTACT US ENG RUS Unmet need Our solution Pipeline Publications Intellectual property New heights in CML therapy Improving the efficacy and safety in the treatment of resistant forms of chronic myelogenous leukemia, including the variant with T315I mutation Mutation T315I under sight Efficacy against clones of CML tumor cells with T315I mutation in the proto-oncogene BCR-ABL Suppression of the emergence of resistance Suppression of the emergence of resistant forms of CML in experiments with directed mutagenesis of CML tumor cells When resistant to two or more Abl inhibitors Investigating efficacy and safety in patients resistant to at least two Abl inhibitors Advanced phases of CML Investigating the efficacy in the accelerated phase and blast crisis and potentials in the therapy of Ph + acute lymphoblastic leukemia For Patients When deciding to participate in the trial, please, contact the |
HTTP Headers
HTTP/1.1 200 OK
Date: Tue, 21 Dec 2021 08:43:32 GMT
Content-Type: text/html; charset=UTF-8
Connection: keep-alive
last-modified: Wed, 06 Oct 2021 10:26:56 GMT
vary: Accept-Encoding
x-frame-options: SAMEORIGIN
x-host: fusion-pharma.com
cache-control: max-age=0
cache-control: public
CF-Cache-Status: DYNAMIC
Report-To: {"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v3?s=JIL%2FbExtVAYy5CfSolWIVjczxHqOoqCtJ1R9IE8I9%2FKMCvGtf7aYZ7bxyL78h7qBeX3K9ZQaHdzuRy60dEO4NeXbRae0aDaJ%2FdnvaLK%2B%2FVAhO4n%2BdxXDWIPk%2Be4Ap54kj3q4Ww%3D%3D"}],"group":"cf-nel","max_age":604800}
NEL: {"success_fraction":0,"report_to":"cf-nel","max_age":604800}
Server: cloudflare
CF-RAY: 6c0fd2c41cf219ae-EWR
alt-svc: h3=":443"; ma=86400, h3-29=":443"; ma=86400, h3-28=":443"; ma=86400, h3-27=":443"; ma=86400
|
fusion-pharma.com Whois Information
Domain Name: FUSION-PHARMA.COM Registry Domain ID: 1849509487_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.nic.ru Registrar URL: http://nic.ru Updated Date: 2021-03-01T08:27:20Z Creation Date: 2014-03-07T09:04:28Z Registry Expiry Date: 2022-03-07T09:04:28Z Registrar: Regional Network Information Center, JSC dba RU-CENTER Registrar IANA ID: 463 Registrar Abuse Contact Email: tld-abuse@nic.ru Registrar Abuse Contact Phone: +7 (495) 994-46-01 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: DEB.NS.CLOUDFLARE.COM Name Server: MATT.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2021-12-24T08:14:58Z <<< |